🔍

FORTIS - Fortis Health.

📊 NSE: FORTIS 🏢 Healthcare 📅 Last Updated: 12/13/2025 22:09

📢 Recent Corporate Announcements

Fortis Healthcare Completes Merger of Four Subsidiaries into Fortis Hospitals

🟢 POSITIVE ⭐ 7/10

M&A 📅 02 Mar 2026, 01:59 AM

Fortis Healthcare has announced that the merger of four of its wholly-owned subsidiaries into Fortis Hospitals Limited (FHsL) became effective on March 1, 2026. The entities absorbed include Fortis Emergency Services, Fortis Cancer Care, Fortis Health Management (East), and Birdie & Birdie Realtors. This consolidation follows the filing of certified NCLT orders from the Delhi and Chandigarh benches with the Registrar of Companies. The move is designed to simplify the corporate structure and enhance operational efficiency across the group.

Merger of four wholly-owned subsidiaries (FESL, FCCL, FHMEL, and B&B) into Fortis Hospitals Limited is now effective.
The effective date of the Scheme of Arrangement is confirmed as March 1, 2026.
NCLT orders from Delhi and Chandigarh benches were filed via Form INC-28 with the ROC.
The restructuring aims to reduce administrative overheads and streamline the organizational hierarchy.

💡 Investors should view this as a positive administrative cleanup that simplifies the company's complex subsidiary structure. No immediate portfolio changes are necessary as the entities were already 100% owned.

Fortis Healthcare Q3 FY26: EBITDA Jumps 34.8%, Margin Expands to 22.3% Amid Strategic Acquisitions

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 20 Feb 2026, 01:13 PM

Fortis Healthcare reported a strong Q3 FY26 with consolidated revenues growing 17.5% YoY to INR 2,265 crores, driven by a 19.4% growth in the hospital segment. Operating EBITDA surged 34.8% to INR 505 crores, reflecting significant margin expansion to 22.3% from 19.4% YoY. While reported PAT dipped to INR 197 crores due to a one-off INR 55 crore labor code expense, operational performance remained robust with ARPOB rising 4.5% to INR 2.56 crores. The company continues its aggressive expansion, recently acquiring People Tree Hospital in Bengaluru for INR 430 crores and adding 750 beds during the year.

Consolidated EBITDA grew 34.8% YoY to INR 505 crores with margins expanding 290 bps to 22.3%.
Hospital business revenue increased 19.4% to INR 1,938 crores, supported by a 4.5% rise in ARPOB to INR 2.56 crores.
Acquired 125-bedded People Tree Hospital in Bengaluru for INR 430 crores with plans to expand to 300 beds.
Agilus Diagnostics reported a sharp margin improvement to 23.1% from 14.4% in the previous year.
Net debt stands at INR 2,547 crores (1.24x Net Debt/EBITDA) following recent inorganic growth investments.

💡 Investors should focus on the strong operational margin expansion and the successful integration of new acquisitions. The temporary dip in PAT due to labor code provisions is a non-recurring item, making the core business growth trajectory attractive.

Fortis Promoter NTK Amends ₹10,930 Crore Lawsuit Against Daiichi Sankyo in Japan

🔵 WATCH ⭐ 7/10

LEGAL 📅 19 Feb 2026, 04:50 PM

Northern TK Venture (NTK), the promoter of Fortis Healthcare and a subsidiary of IHH Healthcare, has amended its legal claim against Daiichi Sankyo in the Tokyo District Court. NTK is seeking damages totaling approximately INR 10,930 Crores for losses related to tortious claims and defamation. The latest amendment seeks to prevent Daiichi Sankyo from obstructing future investments or corporate actions in Fortis and Fortis Malar through defamatory statements to SEBI. This legal action follows the successful completion of the mandatory open offers in November 2025.

NTK filed a petition to amend its claim against Daiichi Sankyo in the Tokyo District Court on February 12, 2026.
The total claim amount for tortious losses stands at INR 109,299,359,054 (approx. INR 10,930 Crores).
The amendment aims to restrain Daiichi Sankyo from obstructing future corporate exercises or share acquisitions in Fortis.
This litigation follows the completion of IHH's mandatory open offers for Fortis and Malar on November 10, 2025.

💡 Investors should monitor the progress of this litigation as it affects the promoter's ability to conduct future corporate actions without interference. While it doesn't impact daily operations, the massive claim amount and the attempt to secure injunctive relief are significant for long-term strategic stability.

Fortis Healthcare Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 16 Feb 2026, 10:47 PM

Fortis Healthcare has officially released the audio recording of its investor and analyst meet held on February 16, 2026. The meeting focused on the company's un-audited standalone and consolidated financial results for the third quarter and nine-month period ended December 31, 2025. This disclosure is a routine regulatory requirement under SEBI (LODR) Regulations to ensure transparency for all shareholders. Investors can access the recording via the provided link on the company's investor relations website.

Audio recording of the Q3 FY26 earnings call is now available for public access.
The call was conducted on February 16, 2026, at 11:00 AM IST.
Discussion covered un-audited standalone and consolidated financial results for the quarter ended Dec 31, 2025.
The filing is compliant with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 Investors should listen to the recording to understand management's commentary on hospital occupancy rates and the performance of the diagnostics business. No immediate portfolio changes are recommended based on this procedural filing.

Fortis Q3 Standalone Revenue Rises 20.7% YoY to ₹443 Cr; New ESOP Scheme Approved

🔵 WATCH ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 07:59 PM

Fortis Healthcare reported a 20.7% YoY growth in standalone revenue from operations to ₹442.93 crore for the quarter ended December 31, 2025. However, standalone net profit declined by 28.2% YoY to ₹28.40 crore, primarily due to a significant spike in finance costs and professional fees. The board has also approved a new Employee Stock Option Scheme (ESOP 2026) covering 1.51 crore shares to incentivize talent. Investors should note that legal overhangs regarding past promoter transactions and SFIO investigations remain ongoing.

Standalone Revenue from operations increased to ₹44,293 lacs from ₹36,687 lacs in the previous year's quarter.
Standalone Net Profit for Q3 FY26 stood at ₹2,840 lacs compared to ₹3,956 lacs in Q3 FY25.
Finance costs more than doubled YoY, rising from ₹2,651 lacs to ₹5,566 lacs in the current quarter.
Board approved ESOP 2026 scheme with a pool of 1,50,99,163 options, each convertible into one equity share.
Ongoing SFIO investigations and Supreme Court-directed forensic audits regarding RHT Health Trust transactions continue to be monitored.

💡 While top-line growth is healthy, investors should monitor the rising finance costs and the impact of the new ESOP scheme on equity dilution. The long-term legal risks associated with past promoter actions remain a critical factor for the stock's valuation.

Fortis Q3 FY26: Revenue up 17.5% to ₹2,265 Cr, Operating EBITDA jumps 34.8%

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 13 Feb 2026, 07:17 PM

Fortis Healthcare reported a strong operational performance for Q3 FY26, with consolidated revenues growing 17.5% YoY to ₹2,265 crore. Operating EBITDA saw a significant jump of 34.8% to ₹505 crore, driven by margin expansion in both hospital (21.7%) and diagnostic (23.1%) segments. While reported PAT was impacted by a one-time exceptional loss of ₹45.9 crore related to new labor codes, the core business remains robust with a 14% increase in occupied beds. The company also expanded its footprint by acquiring People Tree Hospital in Bengaluru for ₹430 crore in January 2026.

Consolidated Operating EBITDA grew 34.8% YoY to ₹505 Cr with margins expanding to 22.3% from 19.4%.
Hospital business revenue rose 19.4% to ₹1,938 Cr, supported by a 14% increase in occupied beds and higher ARPOB of ₹2.56 Cr.
Diagnostics business (Agilus) saw a sharp margin recovery to 23.1% from 14.4% in the corresponding previous quarter.
Net debt increased to ₹2,547 Cr (1.24x EBITDA) following the Agilus stake acquisition and Shrimann Hospital investment.
Acquired 125-bedded People Tree Hospital in Bengaluru for ₹430 Cr with potential to scale to 300+ beds.

💡 Investors should focus on the strong operational EBITDA growth and significant margin expansion in the diagnostics segment. The inorganic expansion strategy in key clusters like Bengaluru and the recovery in Agilus provide a positive outlook for long-term value creation.

Fortis Q3 FY26: Revenue up 17.5% to ₹2,265 Cr; Operating EBITDA jumps 34.8%

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 13 Feb 2026, 07:13 PM

Fortis Healthcare reported a strong operational performance for Q3 FY26, with consolidated revenues growing 17.5% YoY to INR 2,265 Cr. Operating EBITDA saw a significant jump of 34.8% to INR 505 Cr, driven by margin expansion in both hospital (21.7%) and diagnostic (23.1%) segments. While Profit After Tax fell 22.4% to INR 197 Cr due to a one-time exceptional loss related to new labor codes, Profit Before Tax (before exceptions) grew 21.9%. The company also strengthened its footprint through the INR 430 Cr acquisition of People Tree Hospital in Bengaluru.

Consolidated Revenue grew 17.5% YoY to INR 2,265 Cr, with Hospital business contributing INR 1,938 Cr.
Operating EBITDA margins improved significantly to 22.3% from 19.4% in the previous year's quarter.
Diagnostics business (Agilus) showed a sharp recovery with EBITDA margins rising to 23.1% from 14.4%.
Net debt increased to INR 2,547 Cr (1.24x EBITDA) following acquisitions of Agilus PE stake and Shrimann Hospital.
Acquired 125-bedded People Tree Hospital in Bengaluru for INR 430 Cr to expand southern presence.

💡 Investors should focus on the robust 34.8% growth in operating EBITDA and margin expansion rather than the exceptional-item-led PAT decline. The aggressive inorganic expansion in Bengaluru and recovery in the diagnostics segment are positive long-term indicators.

Fortis Healthcare Q3 Standalone Revenue Up 20.7% to ₹443 Cr; Board Approves 1.51 Cr ESOP Pool

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 06:52 PM

Fortis Healthcare reported a standalone revenue of ₹442.93 crore for Q3 FY26, a 20.7% increase from ₹366.87 crore in the same quarter last year. However, standalone net profit for the quarter declined to ₹28.40 crore from ₹39.56 crore YoY, primarily due to a sharp rise in finance costs which reached ₹55.66 crore. The board has also approved a new Employee Stock Option Scheme (ESOP 2026) with a pool of 1.51 crore shares to attract and retain talent. Investors should remain aware of the ongoing SFIO investigations and legal matters regarding erstwhile promoters mentioned in the auditor's report.

Standalone revenue from operations grew 20.7% YoY to ₹442.93 crore in Q3 FY26.
Standalone net profit decreased to ₹28.40 crore in Q3 FY26 compared to ₹39.56 crore in Q3 FY25.
Finance costs surged to ₹55.66 crore in the current quarter from ₹26.51 crore in the previous year's corresponding quarter.
Board approved ESOP 2026 scheme involving 1,50,99,163 equity shares, subject to shareholder approval.
Auditors maintained an emphasis of matter regarding ongoing SFIO investigations and Supreme Court orders related to RHT Health Trust.

💡 Investors should monitor the consolidated financial performance to assess the impact of diagnostic and subsidiary segments. The increase in finance costs and the legal overhang from legacy promoter issues remain key monitorables.

Fortis Healthcare Q3 Standalone Revenue Up 20.7% YoY; Board Approves New ESOP Scheme

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 06:49 PM

Fortis Healthcare reported a standalone revenue of ₹442.93 crore for Q3 FY26, marking a 20.7% growth over the same period last year. However, standalone net profit for the quarter saw a decline to ₹28.40 crore from ₹39.56 crore YoY, largely impacted by finance costs which more than doubled to ₹55.66 crore. For the nine-month period ended December 2025, the company's performance remains strong with a net profit of ₹205.37 crore compared to ₹106.02 crore in the previous year. Additionally, the board has approved a new ESOP scheme for 1.51 crore shares to align employee interests with shareholder value.

Standalone Revenue from operations grew 20.7% YoY to ₹442.93 crore in Q3 FY26.
Net Profit for the quarter stood at ₹28.40 crore, down from ₹39.56 crore in the previous year's corresponding quarter.
Finance costs surged significantly to ₹55.66 crore in Q3 FY26 compared to ₹26.51 crore in Q3 FY25.
Board approved 'ESOP 2026' scheme covering 1,50,99,163 equity shares subject to shareholder approval.
Auditors highlighted ongoing legacy legal matters including SFIO investigations and Supreme Court observations on RHT Health Trust.

💡 Investors should monitor the impact of rising finance costs on the bottom line and keep a close watch on the resolution of legacy legal and regulatory investigations. While the nine-month growth trajectory is positive, the quarterly profit dip suggests a need for cautious observation of operational margins.

Fortis Healthcare Schedules Q3FY26 Earnings Conference Call for February 16, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Feb 2026, 01:52 PM

Fortis Healthcare Limited has scheduled its post-results conference call for Monday, February 16, 2026, at 11:00 AM IST. The management will discuss the company's unaudited financial results for the third quarter and nine-month period ended December 31, 2025. This routine interaction allows analysts and institutional investors to seek clarifications on the company's financial performance and future outlook. The call will be conducted virtually, and a replay facility will be available for one week following the event.

Conference call scheduled for February 16, 2026, at 11:00 AM IST to discuss Q3FY26 results.
Primary India dial-in numbers are +91 22 6280 1307 and +91 22 7115 8208.
International toll-free access provided for UK, US, Singapore, and Hong Kong participants.
A call replay will be accessible from February 16 to February 23, 2026, via +91 22 7194 5757.
The meeting will focus on unaudited financial statements for the period ended December 31, 2025.

💡 Investors should monitor the Q3FY26 financial results release prior to the call and listen for management commentary regarding hospital occupancy rates and diagnostic business performance.

Fortis Shareholders Approve Appointment of Mohd Shahazwan Bin Mohd Harris with 99.39% Majority

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 23 Jan 2026, 04:35 PM

Fortis Healthcare shareholders have approved the appointment of Mr. Mohd Shahazwan Bin Mohd Harris as a Non-Independent & Non-Executive Director via postal ballot. The resolution saw high participation, with 86.73% of outstanding shares being polled. The appointment was passed with an overwhelming 99.39% majority, reflecting strong confidence from both promoters and institutional investors.

Appointment of Mr. Mohd Shahazwan Bin Mohd Harris as Non-Executive Director approved.
Resolution received 650,781,446 votes in favour (99.39%) and 3,975,127 votes against (0.61%).
Promoter group supported the resolution with 100% of their 235.3 million votes.
Public institutional support was high at 98.96% out of 379.7 million votes polled.

💡 This is a routine board appointment with high shareholder consensus; no immediate action is required.

Fortis Shareholders Approve Appointment of Mohd Shahazwan Bin Mohd Harris with 99.39% Vote

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 23 Jan 2026, 04:25 PM

Fortis Healthcare shareholders have approved the appointment of Mr. Mohd Shahazwan Bin Mohd Harris as a Non-Independent & Non-Executive Director via a postal ballot. The resolution received overwhelming support with 99.39% of the 65.47 crore valid votes cast in favor. Promoters and public non-institutions showed near-unanimous support, while institutional investors also backed the move with 98.96% approval. The appointment is effective as of January 22, 2026, following the conclusion of the e-voting process.

Ordinary resolution passed with 65,07,81,446 votes in favor (99.39%) and 39,75,127 votes against (0.61%)
100% of promoter votes (23.53 crore shares) were cast in favor of the appointment
Public institutional investors showed strong confidence with 98.96% favoring the resolution
The appointment was conducted through a postal ballot/e-voting process that ended on January 22, 2026
Mr. Mohd Shahazwan Bin Mohd Harris joins as a Non-Independent & Non-Executive Director liable to retire by rotation

💡 No immediate action is required as this is a routine board appointment. Investors should view the high approval rating as a sign of shareholder alignment with the current management and promoter strategy.

Fortis Healthcare: Delhi High Court Orders Perjury Inquiry Against Third Party

🟢 POSITIVE ⭐ 4/10

LEGAL 📅 22 Jan 2026, 08:53 PM

Fortis Healthcare has received a favorable order from the Delhi High Court regarding a perjury application filed against a third party. The court's order, dated January 21, 2026, initiates an inquiry into the officers of the third party for filing a false affidavit. This legal development is a follow-up to the company's previous disclosure made on December 23, 2025. While the company reports no direct financial implications or claims at this stage, the ruling validates Fortis's legal stance in the ongoing dispute.

Delhi High Court ordered an inquiry on January 21, 2026, into officers of a third party.
The inquiry pertains to the filing of a false affidavit as alleged by Fortis Healthcare.
No financial implications or quantum of claims are currently applicable to this specific order.
The event follows a prior regulatory disclosure dated December 23, 2025.

💡 This is a minor positive legal development that reinforces the company's litigation strategy. No immediate action is required, but investors should track the outcome of the broader dispute.

Fortis Healthcare Receives NCLT Approval for Merger of Four Wholly-Owned Subsidiaries

🟡 NEUTRAL ⭐ 6/10

M&A 📅 16 Jan 2026, 06:45 PM

Fortis Healthcare has received final NCLT approval to merge four of its wholly-owned subsidiaries—FESL, FCCL, FHMEL, and B&B—into Fortis Hospitals Limited (FHsL). The merger is effective from the appointed date of April 1, 2022, and is aimed at streamlining operations and reducing administrative overheads. As the entities involved are all wholly-owned subsidiaries, there will be no issuance of new shares or cash consideration, and the shareholding pattern of the listed parent remains unchanged. FHsL, the transferee company, reported a turnover of INR 12,824.21 million for the period ending March 31, 2025.

NCLT Chandigarh and New Delhi have approved the merger of four subsidiaries into Fortis Hospitals Limited (FHsL).
The merger includes Fortis Emergency Services, Fortis Cancer Care, Fortis Health Management (East), and Birdie & Birdie Realtors.
The appointed date for the scheme is April 01, 2022, with FHsL reporting a turnover of INR 12,824.21 million in FY25.
No cash consideration or share issuance is involved as all entities are 100% owned within the group.
Rationale for the merger is to achieve cost rationalization and simplification of the management structure.

💡 This is an internal corporate restructuring that simplifies the group structure without impacting consolidated financials or shareholding. Investors should view this as a positive step toward operational efficiency and reduced compliance costs.

Fortis Healthcare Receives NCLT Approval for Merger of Five Wholly-Owned Subsidiaries

🟡 NEUTRAL ⭐ 6/10

M&A 📅 16 Jan 2026, 06:44 PM

Fortis Healthcare has received final NCLT approval for the merger of four wholly-owned subsidiaries (FESL, FCCL, FHMEL, and B&B) into Fortis Hospitals Limited (FHsL). The consolidation is designed to enhance operational efficiencies and reduce administrative and managerial overheads. As the entities are wholly-owned, there will be no issuance of new shares or cash consideration, ensuring no dilution for existing shareholders. The primary transferee, FHsL, reported a turnover of INR 12,824.21 million as of March 31, 2025.

NCLT New Delhi and Chandigarh approved the scheme on Jan 5 and Jan 16, 2026, respectively.
The merger involves four subsidiaries being absorbed into Fortis Hospitals Limited (FHsL).
FHsL's turnover stood at INR 12,824.21 million with a paid-up capital of INR 799.88 million as of FY25.
The appointed date for the scheme is April 01, 2022, and it involves no share exchange or cash payout.
Restructuring aims to simplify management structure and achieve cost rationalization in financial reporting.

💡 No immediate action is required as this is an internal consolidation with no impact on the listed entity's shareholding. Investors should monitor for long-term margin improvements resulting from reduced administrative costs.

View All FORTIS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Hospital business revenue grew 19.3% YoY to INR 1,974 Cr in Q2 FY26, while the Diagnostics business (Agilus) grew 7.3% YoY to INR 400 Cr. For H1 FY26, Hospital revenue increased 19% to INR 3,812 Cr and Diagnostics grew 7.3% to INR 768 Cr.

Geographic Revenue Split

Pan-India presence with 27 hospitals. Key facilities in Noida, Faridabad, and FEHI (Fortis Escorts Heart Institute) registered revenue growth in excess of 20% YoY in Q2 FY26. Top 10 facilities contribute 73% to hospital revenues with a 20% operating EBITDA margin.

Profitability Margins

Consolidated PAT for Q2 FY26 was INR 329 Cr, up 70.3% YoY. Net profit margin stood at approximately 14.1%. Hospital business operating margins improved 250 bps to 22.5% in H1 FY26 compared to 20% in H1 FY25.

EBITDA Margin

Consolidated Operating EBITDA margin reached 23.9% in Q2 FY26 vs 21.9% in Q2 FY25, a 200 bps improvement. Diagnostics business reported a 26.1% operating EBITDA margin in Q2 FY26, up from 21.5% YoY.

Capital Expenditure

The company plans to incur capital expenditure of INR 800-1,000 Cr per annum over the next couple of years to fund brownfield expansions and medical equipment upgrades.

Credit Rating & Borrowing

Maintains a strong financial risk profile with a net debt-to-EBITDA ratio of 0.96x as of September 30, 2025, compared to 0.16x in 2024, following debt raised for the Agilus stake acquisition.

⚙️ Operational Drivers

Raw Materials

Medical consumables and pharmacy supplies represent the primary operational costs, though specific percentage of total cost is not disclosed. Rebranding costs for Agilus and Fortis were significant one-off expenses in FY25.

Capacity Expansion

Current network includes 27 hospitals. Planned addition of 1,200-1,500 beds over the medium term. Recent additions include Shrimann Superspecialty (228 beds) and a 15-year lease for a 200-bed facility in Greater Noida with expansion potential to 250 beds.

Raw Material Costs

Not disclosed as a specific percentage of revenue; however, hospital operating EBITDA margins of 22.9% suggest a well-managed cost structure despite inflationary pressures in medical supplies.

Manufacturing Efficiency

Occupancy for Q2 FY26 stood at 71% versus 72% in Q2 FY25. ARPOB (Average Revenue Per Occupied Bed) improved 5.8% YoY to INR 2.51 Cr per annum.

Logistics & Distribution

Diagnostics business operates over 410 labs and 4,330 customer touchpoints as of September 30, 2025, to ensure wide retail reach.

📈 Strategic Growth

Expected Growth Rate

17%

Growth Strategy

Growth will be driven by adding 1,200-1,500 beds via brownfield expansion, increasing ARPOB through a better surgical mix (currently 58%), and scaling the diagnostics business. The company also consolidated its stake in Agilus Diagnostics to 89.20% and acquired the 'Fortis' brand for INR 200 Cr to secure long-term brand usage.

Products & Services

Healthcare delivery services including complex surgeries (oncology, cardiac, neurosciences), outpatient consultations, and diagnostic pathology/radiology tests.

Brand Portfolio

Fortis, Agilus Diagnostics (formerly SRL Diagnostics).

New Products/Services

Expansion into digital healthcare with digital channels (website/app) now contributing 29.5% to hospital revenues, growing 20.4% YoY.

Market Expansion

Expansion in Punjab via Shrimann Hospital and Greater Noida. Evaluating integration of Gleneagles portfolio in Hyderabad and Chennai to enter new geographies.

Market Share & Ranking

Among India's leading healthcare delivery companies; Agilus is a leading player in the diagnostics segment with 410+ labs.

Strategic Alliances

Consolidated 89.20% stake in Agilus by buying out PE investors (NJBIF, Resurgence, and IFC). 15-year lease agreement with RR Lifesciences for Greater Noida hospital.

🌍 External Factors

Industry Trends

The industry is shifting toward digital patient acquisition (29.5% of Fortis revenue) and consolidation of diagnostic players. Fortis is positioning itself by expanding brownfield capacity to meet rising demand for specialty care (oncology, neurosciences).

Competitive Landscape

Competes with other major hospital chains like Apollo and Max Healthcare, as well as regional diagnostic labs.

Competitive Moat

Moat is built on a pan-India network of 27 hospitals and a massive diagnostic footprint (4,330 touchpoints). Sustainability is supported by the acquisition of the 'Fortis' brand and high clinical talent onboarding in oncology and cardiac sciences.

Macro Economic Sensitivity

Sensitive to healthcare spending trends and insurance penetration. Regulatory caps on cash transactions above INR 2 lakh impact high-value surgical billing.

Consumer Behavior

Increasing preference for digital booking and preventive health checkups; Agilus preventive portfolio now contributes 13% to its revenue.

Geopolitical Risks

Resumption of international patient revenue is a key driver, which is sensitive to global travel stability and medical tourism policies.

⚖️ Regulatory & Governance

Industry Regulations

Subject to National Pharmaceutical Pricing Authority (NPPA) price caps on medical devices and clinical establishment acts across different states.

Taxation Policy Impact

Tax expense for Q2 FY26 was INR 96.6 Cr on a PBT of INR 425.4 Cr, representing an effective tax rate of approximately 22.7%.

Legal Contingencies

Contingent liabilities of approximately INR 2,622 Cr as of March 31, 2024, including income tax matters and medical negligence. Ongoing Supreme Court-directed investigation by the Delhi High Court into the RHT asset purchase and potential forensic audit.

⚠️ Risk Analysis

Key Uncertainties

Outcome of the Hon’ble Supreme Court/High Court litigation regarding RHT assets and the potential for a forensic audit could impact management focus and financial liability.

Geographic Concentration Risk

Significant revenue concentration in North India (Noida, Faridabad, Shalimar Bagh), though the network is pan-India.

Third Party Dependencies

Dependency on medical specialists and clinical talent; the company recently onboarded specialists in oncology and neurosciences to mitigate talent risk.